Weekly Spotlight
CMS’s 2027 Outpatient Rule Targets 340B, Site-Neutral Pay, and Hospital Drug Markups
CMS released its draft Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) rule on Thursday, pairing a proposed 2.4% outpatient payment increase with the most consequential changes to hospital drug and site-of-care payment in years. The rule would reimburse 340B drugs at average sales price minus 33.4%, expand site-neutral payment to certain imaging services, and bar hospitals from marking up discounted drugs for Medicare patients. CMS estimates the changes would cut total drug spending by $5.7 billion in 2027, including about $1.15 billion in beneficiary savings.
The 340B provisions drew the sharpest reaction. The draft would not only lower payment rates but accelerate the timeline for recouping prior overpayments, and hospitals quickly warned of the combined financial hit to safety-net providers. STAT framed it as Medicare’s latest swing at the contested discount program, hospital groups objected to the site-neutral expansion, and patient-facing coverage led with the projected savings on drug costs. Because the 340B cut must be budget-neutral, non-340B providers would see an offsetting payment uplift. Comment deadlines and the final rule will determine how much survives.
Tags: #HOSPITAL #DRUG
Centers for Medicare and Medicaid Services (CMS)
Medicare’s GLP-1 ‘Bridge’ Coverage Goes Live
Medicare’s first pathway to weight-loss drug coverage began July 1. Eligible Part D beneficiaries can now obtain GLP-1 drugs (Wegovy, Zepbound, and others) for a $50 monthly copay through the temporary Medicare GLP-1 Bridge demonstration, which runs through December 2027 and requires a qualifying BMI and prior authorization. The launch departs from Medicare’s longstanding statutory bar on covering weight-loss drugs; KFF estimates nearly 3.8 million beneficiaries could qualify, sharpening questions about the program’s fiscal exposure.
Source(s):
Becker’s Hospital Review
Fierce Healthcare
Healthcare Dive (KFF analysis)
The Hill / ABC News
CMS
Tags: #PATIENT #DRUG #PAYER
Medicaid Work Requirements: Rule, Lawsuit, and Financing Squeeze
The new Medicaid work requirements moved from rulemaking to the courts. A coalition of 24 state attorneys general and two governors sued the administration in federal court in Massachusetts to vacate key parts of the CMS interim final rule, arguing the agency overstepped Congress and adopted a restrictive two-part ‘medically frail’ test. In parallel, new CMS Section 1115 budget-neutrality guidance signaled tighter, prospective limits on state demonstrations, as CBO projections showed the 2025 reconciliation law shrinking federal Medicaid over the decade.
- 24 states, 2 governors sue over the ‘medically frail’ rule
- Medical-frailty test challenges for people with HIV
- New 1115 budget-neutrality guidance constrains demonstrations
- How projected Medicaid spending has changed since the 2025 law
- Modernizing program integrity in self-directed care
Tags: #PATIENT #PAYER #PROVIDER
ACA Marketplace: Enrollment Falls as Subsidies Lapse
New federal data quantified the coverage fallout from the expiration of enhanced ACA premium tax credits. Marketplace enrollment fell about 3 million year over year (from 22.1 million to 19.2 million), with analysts tying the drop to higher net premiums and a federal crackdown on improper sign-ups. At least six insurers have announced marketplace exits for 2027.
- ACA enrollment down ~3M as subsidies expire
- Nearly 3 million fewer people secured coverage
- Bleak 2026 state enrollment picture
- Six insurers exit ACA marketplaces for 2027
Tags: #PATIENT #PAYER
Medicare Advantage Overpayments Under Scrutiny
Pressure on Medicare Advantage (MA) payment kept building. KFF estimated the MA quality bonus program will cost more than $13.4 billion in 2026 and explained coding intensity as a central driver of MA overpayments, which MedPAC pegs at roughly $76 billion above traditional Medicare. Separately, Elevance sued the government over its recalculated star ratings.
- MA quality bonus spending to top $13.4B in 2026
- Decoding MA coding intensity
- Elevance sues over $115M tied to MA star ratings
Tags: #PAYER #PATIENT
Drug Pricing and PBMs: Models, Caps, and a PBM Court Win
Drug-pricing policy advanced on several fronts. Final rules for CMS’s GLOBE (Part B) and GUARD (Part D) most-favored-nation models are under review at OMB, while a Medicaid MFN pilot is drawing limited buy-in from mid-sized manufacturers. At the state level, a Colorado judge blocked a drug affordability board’s price cap on Enbrel, model legislation would let states use Medicare’s maximum fair prices as caps, and the Eighth Circuit dismissed the top PBMs’ countersuit against the FTC.
- GLOBE, GUARD most-favored-nation model rules pending at OMB
- MFN pilot hits a snag with mid-sized drugmakers
- Colorado drug-board price cap on Enbrel blocked
- Model bill would let states use MFP caps
- FTC-PBM dispute ends at the Eighth Circuit
- States move to rein in PBMs
Tags: #DRUG #PAYER
CMS Reconsiders National TAVR Coverage
CMS’s national coverage analysis on transcatheter aortic valve replacement (TAVR) continued to draw attention. The agency opened the analysis (CAG-00430R2) in December 2025 at Edwards Lifesciences’ request to reconsider national coverage for symptomatic and asymptomatic aortic stenosis, with a proposed decision memo due in mid-2026 and completion expected in September. Coverage this week highlighted persistent diagnostic gaps that still delay patients on the path to aortic valve replacement.
Source(s):
Cardiac Interventions Today
Tags: #DEVICE #PROVIDER #PATIENT
Other CMS Regulatory Moves
A cluster of narrower CMS actions rounded out the week, spanning quality reporting, prior authorization, and program integrity.
- CMS proposes hospitals report end-of-life care preferences in EHRs
- WISeR prior-authorization vendor ordered to submit a corrective action plan
- CMS seeks broader power to remove ‘problematic’ providers
- Medicaid directors ask CMS to delay electronic prior authorization to 2030
Tags: #HOSPITAL #PROVIDER
Food and Drug Administration (FDA)
FDA Leadership and Regulatory Direction in Flux
Turnover among senior FDA reviewers continued, with the top gene- and cell-therapy regulator set to step down, even as the administration narrowed its permanent commissioner search to three finalists. Observers debated whether recent reversals on rare-disease drugs signal a return to regular order, and a former FDA AI regulator argued industry is reading the agency’s AI guidance too conservatively.
- Top gene and cell therapy regulator to step down
- FDA commissioner search narrows to three finalists
- Is the FDA returning to form?
- Biopharma is reading FDA’s AI guidance too cautiously
Tags: #DRUG #PROVIDER
Edwards Wins FDA Clearance for Ecliptis LAA Exclusion System
Edwards Lifesciences received FDA 510(k) clearance for its Ecliptis left atrial appendage exclusion system, an implantable clip placed during cardiac surgery to close the LAA and reduce stroke risk in atrial fibrillation patients. The clearance positions Edwards against AtriCure’s AtriClip and Medtronic’s Penditure in the surgical LAA-management market, with a measured rollout expected this year.
Source(s):
MedTech Dive
Tags: #DEVICE #PROVIDER
Pharmacies Warned Off Online HIV Drug Marketplaces
ADAP Advocacy and the Partnership for Safe Medicines warned hospital pharmacies on June 30 to avoid buying discounted HIV medications through online pharmacy-to-pharmacy marketplaces, cautioning the products may be ‘suspect’ under federal supply-chain rules.
Source(s):
Becker’s Hospital Review
Tags: #HOSPITAL #DRUG
Department of Health and Human Services (HHS)
CDC, Vaccines, and RFK Jr.: Politicization Concerns Mount
Scrutiny of vaccine policy under Secretary Robert F. Kennedy Jr. intensified. HHS moved to end the last COVID-19 emergency use authorizations; Senate Democrats released internal emails they say show pressure on CDC over vaccine messaging; and public-health groups launched efforts to shore up vaccine policymaking after the ACIP overhaul. More than half of CDC centers lack permanent leadership, and Sen. Bill Cassidy and Kennedy traded public criticism over whether trust in public health has been restored.
- HHS ends COVID-19 emergency use authorizations
- Internal emails show pressure on CDC over vaccines
- Vaccine Integrity Project to reexamine CDC infrastructure
- More than half of CDC centers lack permanent leadership
- CDC leaders focus on boosting staff
- Opinion: casting doubt on vaccine-effectiveness methods
- Kennedy rejects Cassidy’s broken-promise claim
- Cassidy: trust in public health not restored
- Insurers embrace MAHA as physicians hesitate
Tags: #ALL
Lawmakers Press Eli Lilly Over Withheld 340B Discounts
Members of Congress stepped into a dispute between Eli Lilly and hospitals over the company’s decision to withhold 340B discounts from hospitals resisting its claims-data policy, urging HHS to intervene.
Source(s):
STAT+
Tags: #HOSPITAL #DRUG
Cancer Researchers Warn on White House Grant Rule
The American Association for Cancer Research called proposed OMB grant regulations ‘reckless’ and a ‘major threat’ to the NIH, warning they would expand political control over federal research funding.
Source(s):
Becker’s Hospital Review
Tags: #PROVIDER
NIH’s All of Us Taps Clinical Networks for Real-World Data
The NIH’s All of Us precision-medicine program secured thousands of electronic medical records through patient data-sharing networks to fill gaps in its real-world data, testing a new approach to research data collection.
Source(s):
STAT+
Tags: #PROVIDER #PATIENT
HRSA Opens Rural Health and Pediatric Funding
HRSA opened about $140 million in rural health grants for substance-use treatment, workforce, and telehealth, led by a $64 million Rural Communities Opioid Response Program, while its Pediatric Specialty Loan Repayment Program (up to $100,000 for a three-year service commitment) reached its application deadline.
Source(s):
Fierce Healthcare
HRSA
Tags: #PROVIDER #HOSPITAL
HHS Digests Feedback From Its AI Request for Information
Health-sector respondents to HHS’s sweeping AI request for information asked the department to coordinate AI strategy across agencies, provide governance support, and help evaluate AI tools.
Source(s):
Healthcare Dive
Tags: #PROVIDER
Heard on the Hill
Tax-Exempt Hospital Transparency Bill Advances
The House Ways and Means Committee advanced legislation to sharply expand federal transparency obligations for nonprofit hospitals, with the most extensive requirements, including service-line revenue and cost breakdowns and 340B utilization data, falling on high-revenue systems. Hospital groups pushed back, citing added Form 990 Schedule H compliance burdens.
Source(s):
Inside Health Policy
Becker’s Hospital Review
HFMA
Tags: #HOSPITAL
House Passes Bill Easing ACO Quality Reporting
The House passed by unanimous consent the bipartisan Health Care Efficiency Through Flexibility Act (H.R. 5347), which would ease CMS quality-reporting requirements for Accountable Care Organizations in the Medicare Shared Savings Program.
Source(s):
Ways and Means Committee
Inside Health Policy
MedPage Today
Tags: #PROVIDER #HOSPITAL
States Press Hospital Price Caps
The state push to cap hospital prices gained momentum, with 2026 proposals tying commercial and employer prices to Medicare rates. Delaware would limit hospital prices to 250% of Medicare absent justification, following earlier caps in states such as Indiana.
Source(s):
HFMA
Becker’s Hospital Review
Tags: #HOSPITAL #PAYER
House Democrats Unveil Medicare Advantage Reform Package
More than 40 House Democrats introduced the Saving MEDICARE Act on July 1, targeting MA payment practices, such as upcoding, chart reviews, and favorable selection, that MedPAC estimates make MA more costly than traditional Medicare.
Source(s):
Inside Health Policy
Tags: #PAYER
A Prior-Authorization Bill With Broad Support
A bipartisan prior-authorization bill with wide backing and no scored cost faces the perennial question of whether Congress can move it to passage.
Source(s):
MedPage Today
Tags: #PROVIDER #PATIENT #PAYER
Employers Open a New Front on Direct Contracting
Employer groups and direct-contracting specialists are forming a coalition (tentatively the Direct Care Coalition) to press Congress to expand direct contracting, arrangements in which employers contract directly with hospitals and physician groups for their workers’ care, bypassing health insurers.
Source(s):
Modern Healthcare
Tags: #HOSPITAL #PAYER #PROVIDER
Lawmakers Move to Shield Clinical-Trial Diversity
Congressional Republicans are seeking to protect clinical-trial diversity policy that was swept up in the administration’s broader crackdown on diversity, equity, and inclusion initiatives.
Source(s):
STAT
Tags: #PATIENT #DRUG
Senior E&C Health Democrat Loses Primary
Rep. Diana DeGette (D-Colo.), a senior member of the House Energy and Commerce health subcommittee and a longtime voice on FDA, Medicare, and drug pricing, lost her June 30 primary to a progressive challenger.
Source(s):
NBC News
Tags: #ALL
Notable Notes
Anthropic Moves Into Science and Drug Development
Anthropic used a San Francisco launch to introduce Claude Science, a product tailoring its large language model to laboratories and pharmaceutical research, and said it will begin developing drugs of its own, chiefly to gain hands-on experience with its tools. The moves signal AI model makers embedding directly into pharmaceutical R&D, with eventual implications for FDA review pipelines.
- Anthropic releases Claude Science
- Anthropic to develop drugs of its own
- Claude Science launch, summarized
- Anthropic’s biggest healthcare bets
- A conversation with Anthropic’s CEO on AI and biotech
Tags: #DRUG #PROVIDER
Structural Heart and Valves
New valve data featured at New York Valves 2026, alongside an updated adult congenital-heart guideline. JenaValve’s Trilogy TAVR system showed encouraging results in LVAD patients with aortic regurgitation, and one-year outcomes from the Edwards-affiliated J-Valve early feasibility study were favorable in high-risk patients with severe aortic regurgitation. The 2025 ACC/AHA guideline for adults with congenital heart disease updated recommendations on heart failure, Fontan care, mental health, activity, and pregnancy.
- JenaValve Trilogy TAVR in LVAD patients with aortic regurgitation
- Edwards-affiliated J-Valve one-year outcomes in severe aortic regurgitation
- 2025 ACC/AHA adult congenital heart disease guideline
Note: a forwarded Edwards Lifesciences policy summary on clinical-trial and medical-product-innovation developments was flagged this week but arrived without a public link; confirm a citable source before publishing.
Tags: #DEVICE #PROVIDER #PATIENT
New Loan Caps Hit the Health Workforce
Federal student-loan changes took effect July 1. New caps under the 2025 reconciliation law limit many graduate borrowers to $20,500 a year ($100,000 lifetime) and end Grad PLUS, pushing health-professions students toward pricier private loans. Separately, a federal judge blocked part of a rule that had excluded nursing and physical therapy from the ‘professional programs’ definition governing loan limits.
Tags: #PROVIDER
Academic Health Systems Keep Buying Hospitals
Financial pressure, from staffing shortages and aging infrastructure to heavy public-payer dependence and denials, is accelerating consolidation, with 32 academic health systems announcing or planning hospital deals this year.
Source(s):
Becker’s Hospital Review
Tags: #HOSPITAL
A Split Outlook for Rural Surgical Care
Rural ambulatory surgery centers and independent practices face a divided 2026, with new federal dollars and payment reform on one side and clinic closures and a tightening Medicare landscape on the other.
Source(s):
Becker’s Hospital Review
Tags: #HOSPITAL #PROVIDER #PATIENT
One Year On, the 2025 Budget Law Strains the Safety Net
A year after the 2025 reconciliation law, analysts say its Medicaid and ACA changes are weakening the reproductive and family-planning safety net as demand rises, with CBO estimating roughly 10 million more uninsured over a decade.
Source(s):
KFF
Tags: #PATIENT #PAYER
New Research on Racial Discrimination and Health
A KFF brief reviews the evidence linking experiences of racial discrimination to health outcomes, including chronic stress, mental health, and substance use, and the mechanisms involved.
Source(s):
KFF
Tags: #PATIENT
Biotech Is Booming Into Mid-2026
A sustained biotech stock rally underway since spring 2025 is accelerating into mid-2026, a signal of renewed investor confidence with implications for FDA-regulated product pipelines.
Source(s):
STAT+
Tags: #DRUG